Institutional shares held 179 Million
2.25M calls
484K puts
Total value of holdings $794M
$9.98M calls
$2.15M puts
Market Cap $824M
185,944,992 Shares Out.
Institutional ownership 96.4%
# of Institutions 260


Latest Institutional Activity in BCRX

Top Purchases

Q1 2024
Los Angeles Capital Management LLC Shares Held: 89.6K ($397K)
Q1 2024
Wealth Enhancement Advisory Services, LLC Shares Held: 11.3K ($49.9K)
Q1 2024
Cwm, LLC Shares Held: 1.89K ($8.35K)
Q1 2024
Park Place Capital Corp Shares Held: 237 ($1.05K)
Q1 2024
Mather Group, Llc. Shares Held: 200 ($886)

Top Sells

Q1 2024
Grimes & Company, Inc. Shares Held: 71.4K ($316K)
Q1 2024
Massmutual Trust CO Fsb Shares Held: 70 ($310)
Q1 2024
Advisor Net Financial, Inc Shares Held: 259 ($1.15K)
Q4 2023
Pictet Asset Management Holding Sa Shares Held: 19.6K ($86.8K)
Q4 2023
Millennium Management LLC Shares Held: 1.68M ($7.43M)

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.


Insider Transactions at BCRX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
506K Shares
From 16 Insiders
Grant, award, or other acquisition 486K shares
Bona fide gift 20K shares
Sell / Disposition
128K Shares
From 8 Insiders
Open market or private sale 16.9K shares
Payment of exercise price or tax liability 66.6K shares
Bona fide gift 45K shares

Track Institutional and Insider Activities on BCRX

Follow BIOCRYST PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BCRX shares.

Notify only if

Insider Trading

Get notified when an Biocryst Pharmaceuticals Inc insider buys or sells BCRX shares.

Notify only if

News

Receive news related to BIOCRYST PHARMACEUTICALS INC

Track Activities on BCRX